Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. ADC Market Outlook to 2018
     4.1 ADCETRIS
            4.1.1 Market Potential
            4.1.2 Market Size and Forecasts to 2018
     4.2 Kadcyla
            4.2.1 Market Potential
            4.2.2 Market Size and Forecasts to 2018

5. ADC Pipeline Analysis
     5.1 By Phase
     5.2 By Indication
     5.3 By Drug

6. Current Status of Potential ADCs in Pipeline
     6.1 Glembatumumab Vedotin/CDX-011 - Celldex Therapeutics
     6.2 Coltuximab Ravtansine/SAR3419 - Sanofi
     6.3 Indatuximab Ravtansine /BT-062- Biotest
     6.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
     6.5 Polatuzumab Vedotin /RG7596 - Roche (Genentech)
     6.6 Pinatuzumab Vedotin/RG7593 - Roche (Genentech)
     6.7 Lifastuzumab Vedotin/RG7599 - Roche (Genentech)
     6.8 Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millenium

7. Strategic Collaborations in the ADC Industry

8. Drivers and Challenges

9. Competitive Landscape
     9.1 Seattle Genetics
     9.2 Roche
     9.3 Immunogen, Inc.
     9.4 Immunomedics
     9.5 Agensys, Inc.